Meeting
2021 Gastrointestinal Cancers Symposium
Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients treated in United States clinical practices.
Authors
Amit G. Singal
University of Texas Southwestern, Dallas, TX
Amit G. Singal , Saurabh P Nagar , Abigail Hitchens , Shrividya Iyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 273)
DOI
10.1200/JCO.2021.39.3_suppl.273
Abstract #
273
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.
First Author: Ari David Baron
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Multicenter prospective study to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: LENS-HCC trial.
First Author: Masaharu Tada
Poster
2021 ASCO Annual Meeting
The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.
First Author: David Trueman
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study.
First Author: Stephen Chan